Clinical Trials on Malignant Mesothelioma

Total 4508 results

ProgenaBiome

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma

Mesothelioma | Mesotheliomas Pleural | Mesothelioma Peritoneum | Mesothelioma Malignant | Mesothelioma; Lung | Mesothelioma; Liver | Mesothelioma; Omentum

United States
RS Oncology LLC

Recruiting

Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Effusion, Malignant | Mesotheliomas Pleural | Malignant Pleural Effusion | Mesothelioma; Lung

United Kingdom
Ain Shams University

Completed

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM) (VITMPM)

Malignant Pleural Mesotheliomas

Egypt
Eli Lilly and Company

Completed

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Malignant Pleural Mesotherioma

Japan
University Hospital, Lille
INSERM U1189 ONCOTHAI

Recruiting

The IMmunotherapy Pleural 5-ALA PDT (IMPALA)

Malignant Pleural Mesothelioma | Mesotheliomas Pleural

France
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Recurrent Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant Mesothelioma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Withdrawn

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Malignant Pleural Mesotheliomas (Mpm) | Malignant Pleural Effusions (Mpe) | Epithelial Tumors, Malignant | Pleural Effusions, Malignant | Mesothelin (Msln)

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage I Pleural Malignant Mesothelioma AJCC v7 | Stage IA Pleural Malignant Mesothelioma AJCC v7 | Stage IB Pleural Malignant Mesothelioma AJCC v7 | Stage II Pleural Malignant Mesothelioma AJCC...

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Peritoneal Malignant Mesothelioma | Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Pleural Sarcomatoid Mesothelioma | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma and other conditions

United States
NRG Oncology
National Cancer Institute (NCI)

Terminated

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Stage I Pleural Malignant Mesothelioma AJCC v8 | Stage IA Pleural Malignant Mesothelioma AJCC v8 | Stage IB Pleural Malignant Mesothelioma AJCC v8 | Stage II Pleural Malignant Mesothelioma AJCC v8 | Stage IIIA Pleural Malignant...

United States, Canada
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Withdrawn

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma
National Cancer Institute (NCI)

Completed

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Localized Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Sarcomatoid Mesothelioma | Recurrent Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Institute (NCI)

Active, not recruiting

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Unresectable Solid Neoplasm | Advanced Pleural Malignant Mesothelioma | Advanced Peritoneal Malignant Mesothelioma

United States
National Cancer Institute (NCI)

Terminated

EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer

Primary Peritoneal Cavity Cancer | Malignant Ascites | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Localized Malignant Mesothelioma

United States
Åslaug Helland
Bristol-Myers Squibb; Oslo University Hospital; Ultimovacs ASA

Active, not recruiting

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)

Cancer | Mesothelioma | Mesotheliomas Pleural | Cancer of Lung | Cancer, Lung | Mesothelioma; Pleura | Mesothelioma; Lung

Norway, Denmark, Sweden, Spain, Australia
European Organisation for Research and Treatment...
ETOP IBCSG Partners Foundation

Completed

SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access (SPECTAlung)

Any Stage of Lung Cancer (Any Histotype) | Any Stage of Malignant Pleural Mesothelioma | Any Stage of Any Thymic Malignancy

Spain, Belgium, Ireland, Slovenia, France, United Kingdom, Poland, Italy, Switzerland
National Cancer Institute (NCI)

Terminated

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Epithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural Mesothelioma

United States
Hutchison Medipharma Limited

Recruiting

HMPL-453 in Advanced Malignant Mesothelioma

Advanced Malignant Mesothelioma

China
Health Pharma Professional Research

Withdrawn

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma, Advanced | Malignant Pleural Mesothelioma, Unresectable

Mexico
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma

Canada
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso)

Mesotheliomas Pleural

Italy
Hospices Civils de Lyon

Recruiting

Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma

Peritoneal Malignant Mesothelioma

Belgium, Portugal, France, Germany, India, Norway
Erasmus Medical Center

Recruiting

dENdritic Cell Therapy Combined With SURgEry in Mesothelioma (ENSURE)

Mesotheliomas Pleural

Netherlands
Abramson Cancer Center at Penn Medicine

Recruiting

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Mesotheliomas Pleural

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME)

Advanced Malignant Pleural Mesothelioma

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Pleural Malignant Mesothelioma

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

Malignant Mesothelioma (MPM)

United States
Verastem, Inc.

Terminated

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Relapsed Malignant Mesothelioma

United States, United Kingdom
Polaris Group

Terminated

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (TRAP)

Glioma | Hepatocellular Carcinoma | Uveal Melanoma | Sarcomatoid Carcinoma | Pleural Mesothelioma Malignant Advanced | Peritoneal Mesothelioma Malignant Advanced | Non-squamous Non-small Cell Lung Carcinoma

United States, United Kingdom
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA)

Mesotheliomas Pleural

Netherlands
Abramson Cancer Center at Penn Medicine

Recruiting

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (MPM-PDT)

Epitheliod Malignant Pleural Mesothelioma

United States
Swiss Group for Clinical Cancer Research

Completed

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Malignant Pleural Mesothelioma, Advanced

Switzerland, Italy
Istituto Clinico Humanitas

Completed

Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients

MALIGNANT PLEURAL MESOTHELIOMA

Italy
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Mesothelioma | Mesothelioma, Malignant | Malignant Mesothelioma | Peritoneal Mesothelioma | Malignant Peritoneal Mesothelioma

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Pleural Malignant Mesothelioma

United States
Ontario Clinical Oncology Group (OCOG)
Novartis Pharmaceuticals

Terminated

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy (DOVE-M)

Advanced Malignant Pleural Mesothelioma | MPM

Canada
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Mesothelioma, Malignant | Mesothelioma, Malignant Pleural | Mesothelioma Malignant Advanced

China
AGC Biologics S.p.A.

Completed

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM (NGR019)

Advanced Malignant Pleural Mesothelioma

Italy, Germany, Russian Federation
Instituto Nacional de Cancerologia de Mexico
National Council of Science and Technology, Mexico

Unknown

Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma

Advanced Malignant Pleural Mesothelioma

Mexico
AstraZeneca

Completed

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Part A and B: Advanced Solid Malignancies | Part C: Malignant Mesothelioma

Japan
University of Chicago

Withdrawn

A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy

Malignant Pleural Mesothelioma (MPM)

United States
MedImmune LLC

Active, not recruiting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab)

Unresectable Pleural or Peritoneal Malignant Mesothelioma

United States, Italy, Spain, United Kingdom, Belgium, Canada, Poland, France, Korea, Republic of, Hungary, Russian Federation, Germany, Australia, South Africa, Netherlands, Romania, Sweden, Israel, Denmark

Clinical Trials on Malignant Mesothelioma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations